Changing the Frontline Treatment of Kidney Cancer
BY Gina Columbus
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
New Agents Are Shifting Kidney Cancer Treatment Strategies
BY Gina Columbus
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert  Chung-Han (Joe) Lee, M.D., weighs in.
Size Matters: Examining Obesity's Role in Cancer Outcomes
BY Don Vaughan
Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.
Expert Discusses Immunotherapy Combos in Kidney Cancer
BY Laura Panjwani
Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says. 
What's Next in Immunotherapy?
BY Christian M. Capitini, M.D.
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
Experts Discuss Immunotherapy's Role in the Shifting Landscape in Solid Tumors
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.
TKIs Will Continue to Shape Kidney Cancer Treatment
BY Brielle Urciuoli
TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.
TKI Inhibitor Improves Survival in Metastatic Kidney Cancer
BY Jason M. Broderick
Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.
Cabometyx Bests Sutent in Reducing Risk of Progression or Death in Metastatic Kidney Cancer
BY Jason M. Broderick
In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.
Expert: We're Approaching the Golden Age in Kidney Cancer Care
BY Laura Panjwani
After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Kidney CURE discussion group.
Search Cancer Drugs & Terms